Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies

Mingtao Liu; Hui Gan; Zhiman Liang; Li Liu; Qiwen Liu; Yiyin Mai; Huihuang Chen; Baoying Lei; Shangwei Yu; Huihui Chen; Peiyan Zheng; Baoqing Sun

doi:10.3389/fmicb.2023.1122868

Frontiers in Microbiology (Mar 2023)

Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies

Mingtao Liu,
Hui Gan,
Zhiman Liang,
Li Liu,
Qiwen Liu,
Yiyin Mai,
Huihuang Chen,
Baoying Lei,
Shangwei Yu,
Huihui Chen,
Peiyan Zheng,
Baoqing Sun

Affiliations

Mingtao Liu: National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China
Hui Gan: National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China
Zhiman Liang: National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China
Li Liu: Guangzhou Medical University, Guangzhou, China
Qiwen Liu: Guangzhou Medical University, Guangzhou, China
Yiyin Mai: Guangzhou Medical University, Guangzhou, China
Huihuang Chen: Guangzhou Medical University, Guangzhou, China
Baoying Lei: Guangzhou Medical University, Guangzhou, China
Shangwei Yu: Guangzhou Medical University, Guangzhou, China
Huihui Chen: Guangzhou Medical University, Guangzhou, China
Peiyan Zheng: National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China
Baoqing Sun: National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China

DOI: https://doi.org/10.3389/fmicb.2023.1122868
Journal volume & issue: Vol. 14

Abstract

Read online

COVID-19 pandemic is a global public health emergency. Despite extensive research, there are still few effective treatment options available today. Neutralizing-antibody-based treatments offer a broad range of applications, including the prevention and treatment of acute infectious diseases. Hundreds of SARS-CoV-2 neutralizing antibody studies are currently underway around the world, with some already in clinical applications. The development of SARS-CoV-2 neutralizing antibody opens up a new therapeutic option for COVID-19. We intend to review our current knowledge about antibodies targeting various regions (i.e., RBD regions, non-RBD regions, host cell targets, and cross-neutralizing antibodies), as well as the current scientific evidence for neutralizing-antibody-based treatments based on convalescent plasma therapy, intravenous immunoglobulin, monoclonal antibodies, and recombinant drugs. The functional evaluation of antibodies (i.e., in vitro or in vivo assays) is also discussed. Finally, some current issues in the field of neutralizing-antibody-based therapies are highlighted.

Published in Frontiers in Microbiology

ISSN: 1664-302X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Science: Microbiology
Website: http://www.frontiersin.org/journals/microbiology

About the journal

Abstract

Keywords